Bioline, The PCR Company, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), was founded in London, UK in 1992 by Marco Calzavara, President of Meridian Bioscience Europe. Bioline is a leading manufacturer and distributor of PCR enzymes and molecular biology reagents providing complete solutions to researchers in universities, major research institutions, hospitals, biotech and pharmaceutical firms in virtually every corner of the world.
Bioline’s core strength is its long experience and extensive know-how in PCR and real-time PCR enzymes technology. The PCR reagents portfolio includes all components required for PCR and real-time PCR: DNA polymerases and master mixes, reverse transcriptases, nucleotides, buffers and additives. Bioline’s PCR and real-time PCR products are thoroughly validated with all the major instrument systems on the market.
Marco Calzavara, President of Meridian Bioscience Europe, commented, “Our aim at Bioline for the past 20 years has been to develop high-quality and reliable products that make the difference, delivering consistent results time after time. I am excited to carry on Bioline’s great work as a cutting edge molecular biology company, ensuring that we maintain our reputation as a high-quality and reliable firm.”
Richard L. Eberly, Chief Commercial Officer of Meridian Bioscience, Inc., stated, “Congratulations to the Bioline team on its 20th anniversary of successful operations throughout the world. We are enthusiastic about the success of the merger and impressed by the scientific capabilities of Bioline, as well as, its well-deserved reputation for innovation and quality. We remain committed to expanding the rapidly growing portfolio of highly specialized molecular biology products from Bioline that enable the development of genomic tests utilized by researchers, clinical diagnostic laboratories, diagnostic test manufacturers and biotechnology companies.”ABOUT MERIDIAN BIOSCIENCE, INC. Meridian is a fully integrated life science company that manufactures, markets and distributes a broad range of innovative diagnostic test kits, purified reagents and related products and offers biopharmaceutical enabling technologies. Utilizing a variety of methods, these products and diagnostic tests provide accuracy, simplicity and speed in the early diagnosis and treatment of common medical conditions, such as gastrointestinal, viral and respiratory infections. Meridian’s diagnostic products are used outside of the human body and require little or no special equipment. The Company’s products are designed to enhance patient well-being while reducing the total outcome costs of healthcare. Meridian has strong market positions in the areas of gastrointestinal and upper respiratory infections, serology, parasitology and fungal disease diagnosis. In addition, Meridian is a supplier of rare reagents, specialty biologicals and related technologies used by biopharmaceutical companies engaged in research for new drugs and vaccines. The Company markets its products and technologies to hospitals, reference laboratories, research centers, veterinary testing centers, diagnostics manufacturers and biotech companies in more than 60 countries around the world. The Company’s shares are traded through NASDAQ’s Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com. ADDITIONAL INFORMATION